Akebia and U.S. Renal Care initiate trial of Vafseo for patients on dialysis

Akebia and U.S. Renal Care, a privately held kidney care provider, plan to begin a collaborative clinical trial of recently approved Vafseo. The first patient in this trial is expected to be enrolled this year. The Vafseo Outcomes In-Center Experience – VOICE – trial intends to enroll approximately 2,200 patients who will be randomized to oral Vafseo 300 mg tablets administered three times per week or standard-of-care erythropoiesis-stimulating agents. The primary endpoint is all-cause mortality and the secondary endpoint is all-cause hospitalization. The trial was powered to demonstrate non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization.